ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALX Oncology (Nasdaq: ALXO) granted an inducement stock option to Jeff Knight, Chief Development and Operating Officer, consisting of 800,000 shares on April 16, 2026.

Rhea-AI Summary

ALX Oncology (Nasdaq: ALXO) granted an inducement stock option to Jeff Knight, Chief Development and Operating Officer, consisting of 800,000 shares on April 16, 2026.

The option has an exercise price of $1.68 (equal to the closing price on the grant date) and vests 25% on the one-year anniversary of April 13, 2026, with the remainder vesting monthly thereafter under the 2025 Inducement Equity Incentive Plan, pursuant to Nasdaq Listing Rule 5635(c)(4).

Argus Apr 20 session

+4.79% close to close Open Argus

Details

News Market Reaction – ALXO

In the Apr 20 session, ALXO gained 4.79%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details an inducement stock option grant of 800,000 shares at $1.68 per share for ...

Analysis

This announcement details an inducement stock option grant of 800,000 shares at $1.68 per share for ALXO’s new Chief Development and Operating Officer, formalizing terms previously flagged in SEC filings. It extends a pattern of equity-based incentives used to attract and retain key talent. Investors may track future disclosures on additional grants, overall share count evolution, and how new leadership supports milestones for the company’s oncology pipeline.

Key Figures

Inducement option size: 800,000 shares Exercise price: $1.68 per share Initial vesting: 25% of shares +1 more

Inducement option size

800,000 shares

Stock option grant to Jeff Knight on April 16, 2026

Exercise price

$1.68 per share

Equal to ALXO closing price on grant date

Initial vesting

25% of shares

Vests on one-year anniversary of April 13, 2026

Ongoing vesting

1/48 of shares monthly

Vests monthly after first anniversary, contingent on continued service

Historical Context

5 past events · Latest: Apr 13

5 events

1. Apr 13

   Executive appointment

   24h Move

   +2.9%

   Appointed Jeff Knight as Chief Development and Operating Officer.

2. Feb 27

   Earnings and update

   24h Move

   -10.2%

   Reported 2025 results, extended cash runway and outlined clinical milestones.

3. Feb 19

   Investor conferences

   24h Move

   +12.1%

   Announced participation in multiple Q1 2026 investor conferences and webcasts.

4. Feb 19

   Earnings date

   24h Move

   +12.1%

   Set date and call details for Q4 and full‑year 2025 results.

5. Jan 30

   Equity offering

   24h Move

   +10.8%

   Priced underwritten equity offering to raise about $150M for key programs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

inducement stock option, nasdaq listing rule 5635(c)(4)

2 terms

inducement stock option financial

"approved the granting of an inducement stock option to purchase a total of 800,000 shares"

An inducement stock option is a grant of the right to buy company shares given to a new or existing employee as a special hiring or retention incentive, similar to offering a signing bonus but paid in future stock. Investors care because these options can motivate managers to grow the business and align their interests with shareholders, while also increasing the total number of shares over time and potentially diluting existing ownership and earnings per share.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock option has an exercise price"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 800,000 shares of ALX Oncology’s common stock to Jeff Knight, M.P.H., Chief Development and Operating Officer, on April 16, 2026 in connection with the commencement of his employment. Mr. Knight’s inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and was granted as an inducement material to Mr. Knight to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement stock option has an exercise price of $1.68 per share, which is equal to the closing price of a share of ALX Oncology common stock on the grant date, and vests as follows: 25% of the shares subject to such inducement stock option vests on the one year anniversary of April 13, 2026 and an additional one forty-eighth of the shares subject to such inducement stock option vests monthly thereafter, subject to the employee’s continued service.

About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.

Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com

Media Contact:
Michele Parisi, SparkPoint Healthcare Communications
mparisi@sparkpointpr.com
(925) 864-5028

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ALX Oncology (ALXO) announce on April 17, 2026 about Jeff Knight's compensation?

ALX Oncology announced an inducement option to purchase 800,000 shares for Jeff Knight. According to ALX Oncology, the grant was approved April 16, 2026 and is tied to his employment start under the company’s 2025 Inducement Equity Incentive Plan.

What is the exercise price and grant date for the ALXO inducement option to Jeff Knight?

The inducement option has an exercise price of $1.68 per share, equal to the closing price on the grant date. According to ALX Oncology, the option was granted on April 16, 2026 and priced at that day’s closing market price.

How does the ALXO inducement option vest for Jeff Knight and when does vesting begin?

Vesting begins with 25% vesting on the one-year anniversary of April 13, 2026, then monthly thereafter at one forty-eighth increments. According to ALX Oncology, vesting is subject to Mr. Knight’s continued service with the company.

Under what Nasdaq rule was the ALXO inducement grant made to Jeff Knight?

The grant was provided as an inducement in accordance with Nasdaq Listing Rule 5635(c)(4). According to ALX Oncology, the Compensation Committee approved the inducement stock option to facilitate Mr. Knight’s employment with the company.

Which equity plan governs Jeff Knight’s option grant at ALXO and what limits apply?

Jeff Knight’s option is governed by the ALX Oncology 2025 Inducement Equity Incentive Plan. According to ALX Oncology, the option is subject to the plan’s terms and related award agreements and the company’s standard service-based vesting conditions.